< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
No significant interference observed with available related molecules.
The Quantikine Human PSG-1 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human PSG-1 in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human PSG-1 and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human PSG-1 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human PSG-1.
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.
The recovery of PSG-1 spiked to levels throughout the range of the assay in various matrices was evaluated.
Average % Recovery
Cell Culture Media (n=4)
EDTA Plasma (n=4)
Heparin Plasma (n=4)
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of PSG-1 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Preparation and Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Pregnancy-specific beta-1 glycoprotein 1 (PSG-1) is also known as SP1, PSbG1, or B1G1, and is designated CD66f. PSGs are part of the carcinoembryonic antigen (CEA) family and serve as early biochemical markers of syncytiotrophoblast formation. PSGs, which are produced by syncytial cells in the placenta, are detectable in the maternal plasma as early as 2-3 weeks following fertilization and increase as pregnancy progresses. They are alleged to promote immune tolerance of the semi-allotypic fetus during pregnancy. PSG-1 fosters an anti-inflammatory uterine environment by inducing IL-10, IL-6, and TGF-beta 1 secretion. Additionally, PSG-1 is believed to mediate placental vascular morphogenesis by enhancing VEGF-A production and endothelial tube formation.